The demand for plasmid DNA, a critical component to many biological therapeutics, has grown concurrently with advances and successes in cell, gene and mRNA therapies. A plasmid DNA manufacturing platform can support early activities and facilitate the transition towards GMP production for clinical and commercial supply. Securing the supply of this critical raw material will help biotech and pharma companies throughout the drug development lifecycle of their advanced therapies.
Join the webinar to learn:
The features of a plasmid manufacturing platform process
How starting at the lead identification and tox phases support and expedite the transition towards GMP manufacturing
The advantages of securing plasmid bioproduction services that are fully integrated within viral vector and cell therapy manufacturing capabilities
Matthias Craig, Ph.D.
Sr. Manager Product Development
Matthias Craig, Ph.D., joined Catalent Cell & Gene Therapy through its acquisition of Delphi Genetics in 2021 and is currently the Sr. Manager Product Development focused on plasmid DNA. Prior to Catalent, he spent seven years in several roles at Eurogentec, including project lead, new technology development scientist, and business development for projects related to the production of recombinant proteins and plasmids. He has a doctorate in Molecular Biology and a Master’s in Biology from the University of Liège, Belgium.